The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B‐cell precursor acute lymphoblastic leukaemia in measurable residual disease‐negative remission

Ähnliche Einträge

• Hypomethylating agent and venetoclax are effective salvage therapies in relapsed/refractory early T‐cell precursor acute lymphoblastic leukaemia
  von: Vaibhav Agrawal, et al.
  Veröffentlicht: (2025)
• Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high‐grade hepatotoxicity without adversely impacting outcomes
  von: Jose Tinajero, et al.
  Veröffentlicht: (2024)
• Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T‐cell therapy in Philadelphia chromosome‐positive acute lymphoblastic leukaemia
  von: Tamer Othman, et al.
  Veröffentlicht: (2024)
• Therapy‐related acute lymphoblastic leukaemia in women with antecedent breast cancer
  von: Hoda Pourhassan, et al.
  Veröffentlicht: (2024)
• The Impact of Cytoreduction on Blinatumomab Outcomes for Relapsed or Refractory B‐ ALL With High Disease Burden
  von: Jose Tinajero, et al.
  Veröffentlicht: (2025)